Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/358386329 Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90% reduction in COVID-19 mortality rate, in a dose-response manner: definitive results of a prospective o... Preprint · February 2022 DOI: 10.13140/RG.2.2.20069.68320 CITATIONS READ 0 1 9 authors, including: Lucy Kerr Fernando Baldi Instituto Kerr São Paulo State University 15 PUBLICATIONS 98 CITATIONS 431 PUBLICATIONS 4,650 CITATIONS SEE PROFILE SEE PROFILE Raysildo Barbosa Lôbo Juan Chamie Center for Genetic Engineering and Biotechnology Universidad EAFIT 186 PUBLICATIONS 1,196 CITATIONS 14 PUBLICATIONS 22 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Análise genômica de bovinos da raça Nelore (Bos indicus) para características quantitativas e qualitativas de carcaça e carne View project Beth Israel work View project All content following this page was uploaded by Cadegiani Flávio on 06 February 2022. The user has requested enhancement of the Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90% reduction in COVID-19 mortality rate, in a dose-response manner: definitive results of a prospective observational study of a strictly controlled 223,128 population from a city-wide program in Southern Brazil. Lucy Kerr, MD, ARDMS1, Fernando Baldi, PhD2, Raysildo Barbosa Lôbo, PhD3, Washington Luiz Olivato Assagra4, Fernando Carlos Proença5, Jennifer A. Hibberd, DDS, DPD, MRCDC6, Juan J Chamie-Quintero7, Pierre Kory, MD, MPA8, Flavio A. Cadegiani, MD, MSc, PhD8,9* 1 Instituto Kerr de Ensino e Pesquisa, São Paulo, Brazil Department of Animal Sciences, State University of São Paulo, São Paulo, Brazil 3 Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 4 Centro Técnico de Avaliação Genômica C.T.A.G, Ribeirão Preto, Brazil 5 Itajaí City Hall, Itajaí, Brazil 6 University of Toronto, Toronto, Canada 7 Data Analysis, Universidad EAFIT, Cambridge, USA 8 Front-Line Covid-19 Critical Care Alliance (FLCCC), USA 9 Corpometria Institute, Brasilia, Brazil 2 *Corresponding author: Flávio A. Cadegiani, MD, MSc, PhD Corpometria Institute SGAS 915 Centro Clínico Advance, Rooms 260/262/264, Brasília, DF, Brazil f.cadegiani@gmail.com, flavio.cadegiani@unifesp.br, flavio@flccc.net +55 61 981.395.395 Key-words: COVID-19, SARS-CoV-2, ivermectin, prophylaxis, prevention, coronavirus Abstract Background: Previously, we demonstrated that ivermectin use as prophylaxis for COVID-19 was associated with reductions in COVID-19 infection, hospitalization, and mortality rates, and in the risk of dying from COVID-19, irrespective of regularity and accumulated use of ivermectin, in an observational, prospectively obtained data from a strictly controlled city-wide program in a city in Southern Brazil (Itajaí, SC, Brazil) of of medically-based, optional use of ivermectin as prophylaxis for COVID-19. In this study, our objective was to explore the data obtained from the program to evaluate whether the level of regularity of ivermectin use impacted in the reductions in these outcomes, aiming to determine if ivermectin showed a progressive dose-, regularity-response in terms of protection from COVID-19 and COVID-19 related outcomes. Materials and methods: This is a prospective observational study..